# Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)

> **NCT00778999** · PHASE4 · COMPLETED · sponsor: **Organon and Co** · enrollment: 442 (actual)

## Conditions studied

- Infertility

## Interventions

- **DRUG:** Marvelon

## Key facts

- **NCT ID:** NCT00778999
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10-01
- **Primary completion:** 2008-07-24
- **Final completion:** 2008-07-24
- **Target enrollment:** 442 (ACTUAL)
- **Last updated:** 2022-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00778999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00778999, "Predictive Factors for Ovarian Stimulation Using a Fixed Daily Dose of 200 IU Recombinant FSH (Study 142003)(P05696)". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00778999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*